LDR Holding Corporation has a new CFO with “extensive corporate finance experience including management of two successful Initial Public Offerings.”
IPO Veteran McNamara Named LDR CFO
1 min read Premium comments
That’s how the company described Robert E. McNamara on April 23 while naming him as the company’s new CFO.
Company President and CEO Christophe Lavigne practically teased investors saying that McNamara is joining the company, “during this important period in the growth of our company. He brings extensive private and public company experience which will be valuable to us as we manage our ongoing global expansion and position LDR for the next step in the evolution of the company.”
McNamara has held executive leadership positions with technology and medical device companies over the last two decades. In addition to IPO experience, he has also, according to the company, “managed numerous capital raises, and multiple merger and acquisition transactions in global market environments. He holds a Bachelor of Science from the University of San Francisco and a Masters of Business Administration from the Wharton School of Business at the University of Pennsylvania.
Dennis Hynson, who previously held the position of CFO, will remain with the company as senior vice president global finance. He will lead the worldwide finance team and manage the reporting of LDR’s global direct entities.
LDR offers a portfolio of technologies including the ROI-A and ROI-C stand-alone interbody cages featuring VerteBRIDGE Plating Technology. The company’s Mobi-C Cervical Artificial Disc is currently under review by the FDA for approval for both one and two level indications.
In December 2011, the company announced a move into a larger office and plans to hire for a number of positions across multiple areas in 2012. Earlier in the month, the company received approval to market two spine device systems in China.
The company was founded in 2000 by partners Christophe Lavigne, Hervé Dinville and Patrick Richard in Troyes, France. It is currently headquartered in Austin, Texas.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.